Summary: Mirum Pharmaceuticals' president and chief operating officer executed a stock sale to meet tax withholding obligations tied to vested restricted stock units, while the company disclosed stronger-than-expected product sales for 2025 and an increased revenue outlook for 2026. Mirum also bolstered its rare disease pipeline through a recent acquisition.
According to a Form 4 filed with the Securities and Exchange Commission, Peter Radovich, Mirum Pharmaceuticals NASDAQ:MIRM president and COO, sold 2,631 shares of the company's common stock on February 2, 2026. The shares were sold at a per-share price of $103.3035, producing proceeds of approximately $271,791. The filing states the disposition was made to cover tax withholding obligations related to the vesting of restricted stock units. After the sale, Radovich directly holds 20,655 shares of Mirum Pharmaceuticals.
Beyond the insider transaction, Mirum provided preliminary unaudited net product sales for 2025 of approximately $520 million, which surpassed the upper end of the company’s previous guidance. For 2026, the company issued revenue guidance in the range of $630 million to $650 million, representing potential year-over-year growth of up to 25 percent based on that outlook.
Mirum also announced the completion of its acquisition of Bluejay Therapeutics. The deal adds brelovitug, a late-stage therapy for chronic hepatitis delta virus, to Mirum’s clinical portfolio and forms part of the company’s stated strategy to expand its rare disease treatment offerings.
Analyst response to Mirum’s recent disclosures and results has been notable. H.C. Wainwright raised its price target for Mirum Pharmaceuticals to $130 and maintained a Buy rating, citing 2026 as a pivotal year for the company’s drug candidate volixibat. Baird increased its price target to $95 and pointed to sales that exceeded expectations. Citizens reiterated a Market Outperform rating and set a $140 price target, highlighting strong sales for Livmarli and the broader bile acid portfolio.
These combined items - the insider sale to satisfy tax obligations, preliminary sales that outperformed guidance, an acquisitive move into a late-stage rare disease asset, and upward price-target revisions from multiple firms - together mark a period of significant activity and projected growth for Mirum Pharmaceuticals.
Key points
- Insider sale: Peter Radovich sold 2,631 shares on February 2, 2026, at $103.3035 per share to cover tax withholding tied to vested RSUs; he retains 20,655 shares.
- Financial performance and guidance: Preliminary unaudited net product sales for 2025 were about $520 million; 2026 revenue guidance is $630 million to $650 million, implying up to 25 percent year-over-year growth.
- Strategic expansion and analyst reaction: Mirum completed its acquisition of Bluejay Therapeutics, adding brelovitug, and multiple analysts raised price targets or reiterated favorable ratings based on strong sales and pipeline prospects.
Risks and uncertainties
- Insider transactions do not necessarily indicate company outlook; the sale was reported as tax-related and does not provide information about future insider sentiment.
- Sales figures cited are preliminary and unaudited, which may be subject to future adjustment when audited results are released.
- Forward-looking 2026 revenue guidance represents an estimate and carries customary execution and market risks that could affect actual results.